F073 Granulomatous Disorders of the Adult Skin
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Granulomatous disorders represent a unique group of diseases, both noninfectious and infectious, that require clinical pathological correlation combined with a keen sense of inquiry for underlying systemic disease and pharmacologic utilization. Dermatologists need to be able to differentiate granuloma annulare, sarcoidosis, necrobiosis lipoidica, reactive granulomatous dermatitis and drug-induced granulomatous reactions, evaluate patients for underlying systemic diseases, and treat them with appropriate therapeutic agents. By being aware of the skin manifestations of these abnormal physiologic responses from underlying disease or medication usage dermatologists can improve patient safety, outcome and health care costs.
LEARNING OBJECTIVES
Review granulomatous diseases of the skin, providing a framework to recognize different clinical presentations, interpret dermatopathology, evaluate patients for systemic disease involvement, and develop an approach to treatment
Identify characteristics of and differentiate between Granuloma Annulare, Necrobiosis Lipoidica, Sarcoidosis, Reactive Granulomatous Diseases (IGD/PNGD), Necrobiotic Xanthogranuloma, Cutaneous Crohn Disease, and more
SCHEDULE
7:30 PM
Introduction / Overview
Misha Rosenbach, MD, FAAD
7:35 PM
Granuloma Annulare
Juliana P Berk-Krauss, MD, FAAD
7:45 PM
Sarcoidosis (Part I)
Sotonye Imadojemu, MD, FAAD
7:55 PM
Sarcoidosis (Part II)
Avrom Caplan, MD, FAAD
8:05 PM
IBD (Crohns, Granulomatous Cheilitis, OFG)
Alexandra Coromilas, MD, FAAD
8:15 PM
Necrobiosis Lipoidica & Granuloma Clinical Trials Update
Aaron Mangold, MD, FAAD
8:25 PM
Necrobiotic Xanthogranuloma
Caroline Nelson, MD, FAAD
8:35 PM
Immunosuppression-associated granulomatous dermatitis (RuV+)
Karolyn Wanat, MD, FAAD
8:45 PM
Translational Landscape of Granulomatous Disorders: a 2025 Update - JAKi & more
William Damsky, PhD, MD, FAAD
9:00 PM
Pearls, Pitfalls, & Illustrative Cases
Joseph C. English III, MD, FAAD
9:10 PM
Q&A, wrap up
SPEAKERS
Juliana P Berk-Krauss, MD, FAAD
Avrom Caplan, MD, FAAD
Alexandra Coromilas, MD, FAAD
William Damsky, PhD, MD, FAAD
Joseph C. English III, MD, FAAD
Sotonye Imadojemu, MD, FAAD
Aaron Mangold, MD, FAAD
Caroline Nelson, MD, FAAD
Misha Rosenbach, MD, FAAD
Karolyn Wanat, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Juliana P Berk-Krauss, MD, FAAD
No financial relationships exist with ineligible companies.
Avrom Caplan, MD, FAAD
No financial relationships exist with ineligible companies.
Alexandra Coromilas, MD, FAAD
No financial relationships exist with ineligible companies.
William Damsky, PhD, MD, FAAD
AbbVie – Investigator(Fees); Advanced Cell Diagnostics, Inc. – Investigator(Equipment); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); CSL Behring – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Fees); Epiarx Diagnostics – Consultant (1099 relationship)(Fees); Fresenius Kabi – Consultant (1099 relationship)(Fees); Incite – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); MilliporeSigma – Other(Patent royalties or other compensation for Intellectual Property Rights); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); TWi Biote – Consultant (1099 relationship)(Fees); TWi Biotechnology, Inc. – Consultant(Fees), Consultant (1099 relationship)(Fees), Investigator(Fees);
Joseph C. English III, MD, FAAD
No financial relationships exist with ineligible companies.
Sotonye Imadojemu, MD, FAAD
No financial relationships exist with ineligible companies.
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Atlas Med – Other(Patent royalties or other compensation for Intellectual Property Rights); Boehringer Ingelheim – Consultant(Honoraria); Bristol Myers Squibb – Investigator(Grants/Research Funding); clarivate – Consultant(Grants/Research Funding); Dragonfly Therapeutics – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); EMD Serono – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Insmed – Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Other(Patent royalties or other compensation for Intellectual Property Rights); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Scitech Development – Investigator(Grants/Research Funding); Solgenix, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria);
Karolyn Wanat, MD, FAAD
No financial relationships exist with ineligible companies.